Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 13/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747949 | 0.83 | HSD11B1 (0.46) | MRGPRX4 | |
| SCHEMBL3739872 | 0.82 | GRM5 (0.47) | VNN1MRGPRX4 | |
| SCHEMBL3747705 | 0.82 | MRGPRX4 (0.47) | VNN1MRGPRX4FFAR1 | |
| SCHEMBL3735490 | 0.81 | MRGPRX4 (0.47) | MRGPRX4 | |
| SCHEMBL27940180 | 0.77 | VNN1 (0.56) | GSK3BVNN1FFAR1FFAR4 | |
| SCHEMBL3747714 | 0.76 | DAO (0.43) | MRGPRX4 | |
| SCHEMBL3732884 | 0.76 | DAO (0.43) | MRGPRX4 | |
| SCHEMBL3740255 | 0.75 | DAO (0.42) | VNN1MRGPRX4FFAR1 | |
| SCHEMBL3730577 | 0.74 | CTNNB1 (0.52) | — | |
| SCHEMBL3743226 | 0.74 | PIM1 (0.42) | MRGPRX4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| CN-101627007-A | Aminoamides as orexin antagonists | HOFFMANN LA ROCHE | 2010-01-13 | — | — | CN | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | GSK3B 2132/4885VNN1 3924/4885MRGPRX4 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.